Abstract:Abstract Background: The progression of cancer is intricately linked to systemic immunity. However, within the hepatocellular carcinoma (HCC) patients undergoing anti-PD-1 therapy, there exists a paucity of comprehensive reports concerning the prognostic implications of immunological markers within peripheral blood. The primary objective of this investigation is to meticulously identify predictors indicative of the response to anti-PD-1 therapy in HCC patients, with a specific emphasis on immunological markers within peripheral blood. The overarching goal is to ameliorate patient outcomes through the discernment of these predictive factors. Noteworthy advancements in the treatment of HCC have been achieved through the utilization of immune checkpoint inhibitors (ICIs). Nevertheless, a conspicuous deficiency persists in the current landscape-namely, the absence of a streamlined and accessible peripheral blood-based model for the anticipation of clinical outcomes and the facilitation of judicious treatment stratagems. Methods: A total of 30 HCC patients consecutively treated with anti-PD-1 therapy in Affiliated Hospital of University of Electronic Science and Technology of China between January 2021 and January 2023 were included in the retrospective study. Patients were divided into the tumor-progressive-free (TPF) group and tumor-progressive (TP) group based on the 48-week follow-up evaluation. The correlation between the feature indicators (e.g., immunological indicators, blood parameters and free PD-1 in peripheral blood) and clinical prognosis was analyzed. In order to delve deeper into the impact of IL-2 and IL-10 on the efficacy of immunotherapy, a comprehensive analysis was conducted utilizing integrated RNA sequencing data obtained from the Gene Expression Omnibus (GEO) and Cancer Genome Atlas (TCGA) databases. Mechanistic insights into the regulatory effects of IL-2 and IL-10 on immunotherapeutic outcomes were explored through enrichment analysis and immune cell infiltration analysis. Results: The univariate analysis results demonstrate that IL-2 (0.0045) and IL-10 (p=0.025) were initially screened as differential predictors. Further multivariate analysis identified the ratio of IL-2 and IL-10 (odds ratio (OR) 2.918, 95% confidence interval (CI), 1.191–7.15, p=0.019) as independent prognostic factors. The ratio of IL-2 and IL-10 (AUC=0.884, 95% CI: 0.766-1, p<0.001) presented better prognostic performance than other traditional prognostic indicators. To further extend the relevance between two cytokines and anti-PD-1 therapy, we explored the expression of IL-2 and IL-10 in CD8+ T cells based on publicly available data which were collected from NCBI Gene Expression Omnibus (GEO) database. The results suggested that reduction of the expression of IL-2 (p= 0.0005) and accumulation of the expression of IL-10 (<0.0001) were shown in exhausted T cells compared with effector T cell. Moreover, analysis of The Cancer Genome Atlas (TCGA) dataset reveals that IL-2 and IL-10 exhibit involvement in immune-associated gene sets, encompassing those related to cytokine signaling pathways, innate immunity, and adaptive immunity. The expression patterns of IL-2 and IL-10 are intricately linked to the infiltration of the anti-tumor immune microenvironment by distinct immune cell populations, including B cells, T cells, dendritic cells, monocytes, macrophages, and neutrophils. Conclusion: The research findings indicate a significant correlation between a low ratio of IL-2 to IL-10 and adverse prognosis in hepatocellular carcinoma (HCC) patients. This finding is related to the status of immune cells. In the future, the clinical significance of this indicator is worthy of further validation in large cohort samples, so as to help specify more accurate individualized treatment plan and improve the prognosis of HCC patients.

The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.

Predictive Value of the Biomarker of Peripheral Blood of Lung Carcinoma Patients Responding to PD-1 Treatment: A Real-Word Study.

Plasma Cytokines Interleukin-18 and C-X-C Motif Chemokine Ligand 10 Are Indicative of the Anti-Programmed Cell Death Protein-1 Treatment Response in Lung Cancer Patients

Immunological profiling for short-term predictive analysis in PD-1/PD-L1 therapy for lung cancer

[Peripheral Blood Laboratory Test Results Combined with TCF1+CD8+ T Lymphocytes Ratio to Predict the Response and Prognosis of Immunotherapy to Advanced Lung Cancer]

Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma

Clinical markers predict the efficacy of several immune checkpoint inhibitors in patients with non-small cell lung cancer in China

Dynamic Changes in Blood PD-L1 Expression Predict the Efficacy and Overall Survival of Immune Checkpoint Inhibitor Treatment in Non-Small-Cell Lung Cancer Patients

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer

Prognostic value of the ratio of Interleukin-2 and Interleukin-10 in patients with hepatocellular carcinoma treated with anti-PD-1 therapy

Tumor-Infiltrating PD-1hiCD8+-T-Cell Signature As an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers

PD-1(+) IFN-gamma(+) subset of CD8(+) T cell in circulation predicts response to anti-PD-1 therapy in NSCLC

Prediction Accuracy of Biomarkers for Response to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatment

Immune-inflammatory markers and clinical characteristics as predictors of the depth of response and prognosis of patients with PD-L1 ≥50% metastatic non-small cell lung cancer receiving first-line immunotherapy

Longitudinal High-Dimensional Analysis Identifies Biomarkers of Response to Anti-PD-1 Immunotherapy

Prediction Performance Comparison of Biomarkers for Response to Immune Checkpoint Inhibitors in Advanced Non‐small Cell Lung Cancer

Predictive biomarkers for immune checkpoint inhibitors therapy in lung cancer

A Bioinformatics-Based Immune-Related Prognostic Index for Lung Adenocarcinoma That Predicts Patient Response to Immunotherapy and Common Treatments